drugset / Trial / NCT06487858
A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a first-in-human (FIH) study that will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BGB-R046 as a single agent and in combination with tislelizumab (BGB-A317) in participants with advanced or metastatic immune-sensitive solid tumors.
Timeline
- Start
- 2024-07-16
- Primary completion
- 2026-04-09
- Completion
- 2026-04-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BGB-R046 | Unknown | — | Intravenous |
| Subject | Tislelizumab | Monoclonal antibody | — | Intravenous |